vTv Therapeutics (NASDAQ:VTVT) Rating Lowered to “Sell” at Wall Street Zen

vTv Therapeutics (NASDAQ:VTVT) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday, Wall Street Zen reports.

Other research analysts also recently issued research reports about the stock. Lifesci Capital upgraded shares of vTv Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 2nd. Zacks Research raised vTv Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, September 7th. HC Wainwright cut their price target on shares of vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Weiss Ratings lowered shares of vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Finally, BTIG Research reissued a “buy” rating and issued a $57.00 target price on shares of vTv Therapeutics in a research note on Wednesday, October 14th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $55.83.

vTv Therapeutics Trading Down 5.9%

NASDAQ:VTVT opened at $25.55 on Friday. The firm has a fifty day simple moving average of $30.95 and a two-hundred day simple moving average of $32.90. The stock has a market capitalization of $100.64 million, a price-to-earnings ratio of -24.10 and a beta of 0.21. vTv Therapeutics has a 12 month low of $19.50 and a 12 month high of $44.00.

vTv Therapeutics (NASDAQ:VTVT) last released its earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.08). Equities analysts predict that vTv Therapeutics will post -2.35 earnings per share for the current fiscal year.

About vTv Therapeutics

vTv Therapeutics, Inc (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered small-molecule medicines for chronic diseases. The company’s research has primarily addressed metabolic and neurological disorders, including diabetes and Alzheimer’s disease.

vTv’s development portfolio has included cadisegliatin (also known as TTP399), an oral, liver-selective glucokinase activator being studied as a potential treatment for type 1 diabetes, and azeliragon, an investigational drug designed to inhibit the receptor for advanced glycation end products (RAGE) in Alzheimer’s disease.